Novel Conjugate Shows Promise in HER2-Expressing Cancers

Leggi l'articolo originale


Researchers tested the novel antibody-drug conjugate trastuzumab duocarmazine in patients with heavily pretreated HER2-expressing metastatic cancers, including breast cancer.

Lascia un commento